TBK1 and type 2 diabetes mellitus: Amlexanox is an inhibitor of IKKε and another NF-κB activator TANK-binding kinase 1 (TBK1), that was previously FDA approved for the treatment of apthous ulcers that has been investigated in a Phase 2 trial for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease [86].